Welcure Drugs & Pharmaceuticals Limited has announced a major sourcing and procurement deal worth approximately ₹517 crore with Fortune Sagar Impex Company Limited, Thailand. The mandate is a fee-based sourcing agreement under which Welcure will earn a 5% commission on the cost of goods sourced, translating to an estimated ₹25.85 crore in service income over FY2025-26.
The execution of the contract will proceed on a call-off basis, with the initial lot set to mobilize upon meeting predefined prefunding milestones. The full set of tranches is expected to conclude by 30 September 2026. The mandate covers procurement and sourcing of multiple finished-dosage SKUs under an Ex-Works model.
Importantly, this is not a related-party transaction, and there is no promoter or group entity involvement. Welcure highlighted that the deal expands its fee-based portfolio without any additional balance-sheet exposure.
The buyer will handle packaging, labelling, containerisation, insurance, freight, and destination-country regulatory clearances. The company has committed to providing timely updates as and when each call-off is activated.
